As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...

Amgen Inc. closed 18.42% short of its 52-week high of $346.85, which the company achieved on July 25th.

Citi lowered the firm’s price target on Amgen (AMGN) to $295 from $310 and keeps a Neutral rating on the shares. Ahead of the ...

Amgen (AMGN) closed the most recent trading day at $280.30, moving -0.94% from the previous trading session. The stock's performance was behind the S&P 500's daily gain of 0.92%. Meanwhile, the Dow ...

Today, Benzinga 's options scanner spotted 28 uncommon options trades for Amgen. This isn't normal. The overall sentiment of ...

This December, Amgen received a second state incentive to expand its Holly Springs operations by adding another drug ...

North Carolina achieved a record-breaking year for life sciences investments in 2024. Twenty-five companies announced ...

Amgen Inc (AMGN) stock saw a decline, ending the day at $275.42 which represents a decrease of $-2.46 or -0.89% from the prior close of $277.88. The stock opened at $276.26 and touched a low of $273.5 ...

Situated in the core of the NC Research Triangle, the site at Camp Helix Innovation Park is a substantial regional investment ...

Amgen executives and employees, local and state elected dignitaries, and an assortment of other local economic development ...

Rep. Andy Ogles (R-Tenn.) proposed an amendment to the U.S. Constitution that would allow President Trump to serve a third ...

Amgen Inc. closed 19.88% short of its 52-week high of $346.85, which the company reached on July 25th.